Chapter 45: Drugs of Abuse

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So usually when you study pharmacology, there's this comforting sense of predictability, you know?

Oh, absolutely.

It's usually a very neat process.

Right.

A patient presents with a specific pathology.

You administer a molecule designed to bind to a very specific target.

The physiological equilibrium is restored and, well, you move forward.

It's a clean,

rational puzzle.

Because it relies entirely on the premise of healing.

I mean, it's a measured, targeted intervention to correct an imbalance.

But the moment you encounter the pharmacology of abuse, which is what we're tackling today, that rational puzzle is just completely obliterated.

Yeah.

You are looking at an entirely rogue landscape.

Exactly.

These molecules, they aren't designed to heal.

They are engineered to aggressively hijack the body's natural signaling infrastructure, you know, to fundamentally alter perception, mood, consciousness.

It really represents an ongoing microscopic arms race because on one side you have human physiology attempting to maintain homeostasis.

And on the other, you have this illicit chemistry constantly evolving to outpace both natural biological defenses and, frankly, clinical detection.

Which makes it fascinating, but also terrifying.

Welcome to a special deep dive from the Last Minute Lecture Team.

We are bypassing the typical syllabus speak and plunging straight into the core mechanisms that drive this arms race.

We are so excited to get into this with you.

Our mission today is to guide you through the intricate receptor logic detailed in Chapter 45 of your Lippincott Illustrated Reviews, Pharmacology, the seventh edition text.

And to understand the stakes, you really just have to look at the sheer scale of the data in the overview.

Right.

Looking at figures forty five point one and forty five point two, we are talking about nearly twenty four point six million active users of illicit drugs in a single year based on the 2015 data from the chapter, which is just a massive demographic spread.

It is.

I mean, marijuana vastly outpaces the rest, accounting for nearly 20 million of those users.

But then you look at alcohol and the non -medical use of prescription drugs, which represents a massive six point five million people, followed by cocaine at roughly one point five million.

And when you analyze the dependence potential across these different molecular classes, which is beautifully laid out in figure forty five point three,

the physiological divergence is pretty stark, right?

Oh, incredibly stark.

You have narcotics like heroin and fentanyl, and they stretch to the absolute highest tier of severe physical dependence.

They're shoulder to shoulder with ethanol and nicotine.

Oh, yeah.

But then substances like cannabis and LSD, they demonstrate a remarkably low potential for severe physical dependence.

They are just playing by entirely different physiological rules.

So let's trace those rules, starting with the molecules that force the body's fight or flight system, the sympathetic nervous system into absolute overdrive.

The sympathomimetics and cocaine provides the quintessential baseline for this mechanism.

OK, so paint a picture of that for us.

What's happening at the cellular level?

So if you look at figure forty five point four, imagine a normally functioning synapse.

Usually neurotransmitters like norepinephrine, serotonin and dopamine, they transmit a signal across the synaptic cleft and then they're immediately recycled by presynaptic reuptake transporters.

So the system is designed to be highly efficient, right?

To prevent continuous uncontrolled stimulation.

Exactly.

But cocaine basically acts as a molecular barricade.

It binds directly to those reuptake transporters and just jams them shut.

So the neurotransmitters have nowhere to go?

None.

They become trapped in the synaptic cleft, relentlessly bombarding the postsynaptic receptors.

And that localized flood of dopamine, specifically in the brain's pleasure centers, is what generates that profound acute state of euphoria.

OK, but wait, a quick question on the routes of administration.

Why isn't cocaine just, you know, taken as a pill?

Well, oral administration of cocaine yields terrible bioavailability.

The molecule is highly susceptible to destruction in the gut and then it faces aggressive first metabolism by the liver.

So to achieve that massive dopamine surge, the user basically has to circumvent the digestive tract entirely.

Right.

That's why the consumption methods are so specific.

Insufflating or snorting the powder, altering it into a free base form like crack so it can be volalized and smoked, or just injecting it directly into the venous system.

Because those routes bypass the liver.

Yeah, exactly.

They hit the richly perfused vascular beds of the lungs or the systemic circulation directly, meaning the drug crosses the blood brain barrier in seconds.

Wow.

But, you know, that rapid peak concentration means an equally rapid clearance.

The intense euphoria crashes into profound dysphoria.

And that vicious rapid fire cycle,

extreme positive reinforcement followed immediately by negative reinforcement.

That is the engine of cocaine addiction.

It is.

And the peripheral consequences of that sympathetic surge are catastrophic.

Figure 45 .5 walks through this terrifying domino effect.

You're looking at a systemic cascade of vascular and neurological failure.

The central nervous system stimulation bleeds into severe tachycardia, massive peripheral vasoconstriction.

Blood pressure skyrockets.

The myocardium demands oxygen it just cannot get, leading to severe dyspnea, ischemic damage, cardiac arrhythmias, and frequently fatal seizures.

And the chemistry becomes substantially more lethal when multiple substances are combined, which is a key drug interaction you have to know.

What happens when a user mixes cocaine and ethanol?

That is a deadly combination.

The concurrent ingestion forces the liver to process both simultaneously, resulting in the synthesis of a highly toxic secondary metabolite known as cocafine.

Cocaline.

And that drastically amplifies the cardio toxicity, right?

It does.

It extends the half -life of the stimulant effect, but it severely escalates impulsive aggressive behaviors and vastly increases the probability of a sudden myocardial infarction.

So when a patient presents in the emergency department in the throes of a severe sympathomimetic crisis,

they're profoundly hypertensive,

agitated,

maybe seizing.

How do you treat that?

Because reaching for a targeted cardiac drug first might seem intuitive, but it's actually not the first line choice.

Right.

It's counterintuitive.

If you actually reach for a central nervous system depressant, administering a benzodiazepine like lorazepam attacks the crisis at its neurological root.

Because it calms them down?

Yes.

It provides vital anxiolytic action to calm the severe agitation, and it raises the seizure threshold to halt the convulsions.

But critically, it addresses the hyperthermia.

Because that combination of relentless muscular hyperactivity and intense vasoconstriction traps massive amounts of heat within the body.

Exactly.

Hyperthermia is a primary mechanism of mortality in cocaine toxicity.

So lorazepam suppresses that central overdrive, allowing the body to begin dissipating heat.

Okay, so that's cocaine.

But then you have amphetamines, like methamphetamine, which take this hyperstimulation and dial it up through a far more invasive mechanism.

Yeah, they do not just sit on the outside of the neuron blocking the reuptake pumps like cocaine does.

They actually go inside, right?

They act as intracellular invaders.

They penetrate the presynaptic nerve terminal, force their way into the storage vesicles and actively expel the biogenic amines into the cytoplasm.

Oh, wow.

And this massive intracellular buildup actually forces the reuptake transporters to run in reverse, pumping vast quantities of neurotransmitters out into the synapse.

It's basically an active cellular eviction.

And because the amphetamines are continually forcing neurotransmitters out from the inside, the physiological stimulation endures significantly longer than the brief acute rush associated with cocaine.

Exactly.

It's a much longer lasting stimulation, though often with less acute early euphoria compared to the immediate hit of cocaine.

So what happens when underground chemists take these stimulant structures and just tweak them a little bit, which leads us directly into part two of our deep dive, MDMA and synthetic cathinones?

Right.

So let's look at Methylenedioxymythamphetamine, or MDMA, commonly known as Ecstasy or MOLLE.

It retains those stimulant properties, but introduces a massive targeted assault on the serotonergic system.

Figure 45 .6 illustrates this neurochemical triple threat perfectly.

It really does.

MDMA blocks the reuptake of serotonin.

It forces the massive release of intracellular serotonin into the synaptic cleft.

And simultaneously, it completely inhibits the synthesis of new serotonin.

So the neuron is basically wringing out every last drop of its serotonin reserves while preventing any replenishment?

Precisely.

This generates an overwhelming synaptic flood, driving the intense empathy, altered tactile sensation and profound euphoria characteristic of the dorg.

But the inevitable consequence is absolute intracellular depletion.

When the molecule is finally cleared, the brain is fundamentally empty of serotonin.

And the systemic side effects of that specific serotonergic storm are highly recognizable clinically.

The profound neuromuscular overstimulation manifests as extreme bruxism, which is teeth grinding and trismus or jaw clenching.

Which explains the really unique clinical science, right?

Like users at raves using baby pacifiers to mitigate severe dental trauma.

That's exactly why they do it.

And managing an acute MDMA crisis requires confronting both that sympathetic overdrive and the unique serotonergic threat.

So benzos are still the front line for calming the patient and cooling them down.

Yes, benzos for the hyperthermia and agitation.

But that massive serotonin dump puts the patient at severe risk for serotonin syndrome.

And if that hyperthermia and autonomic instability become life -threatening, what's the pharmacological countermeasure?

You deploy cyproheptadine.

It functions as a direct serotonin antagonist, binding to the 5 -HT receptors and halting the toxic cascade.

The tricky clinical hurdle, though, is that cyproheptadine is primarily available in an oral formulation.

Which is obviously complicated to administer to a seizing or unconscious patient in a critical acute care scenario.

Very complicated.

And, you know, the entire evolution of MDMA illustrates the adaptability of illicit pharmacology.

Underground chemists are continuously synthesizing derivatives to evade legislative bans and standard clinical detection.

Which brings us to synthetic cathinones, frequently referred to as bath salts.

Right.

These are derived from the psychoactive compounds in the cot plant.

And it's just wild.

They distribute these molecules under deliberately deceptive labeling,

like pond water cleaner or plant food, specifically to skirt legal oversight.

It's a complete evasion tactic.

And crucially, for clinical practice, these altered structures easily evade routine urine toxicology screens.

Even though they flood the brain exactly like the drugs we just talked about.

Exactly.

Despite the chemical masking, their pharmacodynamics mirror classic amphetamines.

They trigger massive catecholamine release and inhibit reuptake, resulting in severe psychotomimetic effects, profound agitation, and intense sympathomimetic toxicity.

And that psychotomimetic effect, the way it distorts reality, provides a natural segue into our third pharmacological class.

We are moving from molecules that force an excessive physical output to those that primarily distort sensory input and alter perception.

The hallucinogens, driven historically by lysergic acid diphylamide, or LSD.

So what is the mechanism there?

LSD demonstrates extraordinary receptor specificity and potency.

It operates as a highly potent partial agonist, specifically at the five HT2A serotonin receptors in the central nervous system.

The pharmacodynamics of LSD actually answer a really common question.

Why don't you typically see daily compulsive usage patterns with LSD, like you do with cocaine or opioids?

It's a great question, and it comes down to physiology.

The human body basically refuses to tolerate continuous phi HT2A overstimulation.

Repeated exposure to LSD triggers an immediate aggressive downregulation of those specific receptors.

So the neuron essentially pulls the receptors inward, away from the cell membrane.

Exactly.

It creates profound physiological tolerance almost instantly.

The molecule simply loses its target.

That's fascinating.

And while the physical adverse effects, like midrasis, which is dilated pupils, tachycardias, sweating, are relatively mild compared to the sympathomimetics, the neurological threat is severe, right?

Very severe.

The primary risk is extreme psychiatric distortion.

A bad trip involves terrifying panic and a complete collapse of reasoning, which frequently results in catastrophic erratic behavior.

Now, this profound sensory alteration contrasts sharply with the most widely consumed illicit substance in the data, cannabis sativa or marijuana.

Yes.

Looking at figure 45 .8, marijuana represents the primary initiator drug, with over 65 % of illicit substance users starting their exposure there.

And the primary psychoactive alkaloid, delta -9 -tetrahydrocannabinol, or THC, operates through an entirely distinct endogenous pathway.

Right.

THC specifically targets and activates the CB1 cannabinoid receptors.

And these receptors are densely concentrated in specific neural architecture.

For instance, high populations in the amygdala alter emotional processing.

And massive concentrations in the hippocampus directly interfere with memory formation.

Which ties perfectly into a clinical scenario from the chapter's study questions.

Imagine a 15 -year -old patient who reports using marijuana to self -medicate for anxiety.

As a clinician, where does your immediate warning need to focus?

It must focus on the hippocampus.

The activation of those CB1 receptors induces significant short -term memory impairment.

And because the adolescent brain is actively developing its synaptic pathways,

this neurological disruption is vastly more pronounced, right?

Oh, absolutely.

It is highly pronounced in adolescents, and potentially enduring compared to an adult brain.

Now, while the illicit use of the raw plant material is ubiquitous, we should review the legitimate clinical uses.

Clinical pharmacology has successfully harnessed specific phyto -cannabinoids and synthetic derivatives for targeted therapeutic use.

Yes, for example, dronabinol and nabolone.

These act as highly effective adjuvants for managing severe chemotherapy -induced nausea and combating the profound cachexia or wasting syndrome associated with advanced AIDS or oncology patients.

And there's also nabiximals.

Right.

Nabiximals is an oral mucosal spray derived directly from the plant extracts, and it provides targeted relief for the debilitating muscle spasticity associated with multiple sclerosis.

However, the medical application of these specific molecules must be strictly differentiated from the illicit market of synthetic cannabinoids.

I'm talking about the street formulations marketed as SPICE or K2.

Yeah, that is a crucial distinction.

Those are not just highly concentrated marijuana.

They are entirely distinct lab -synthesized molecules sprayed onto inert plant matter.

And the adverse effects are severe.

Very.

Their molecular affinity for the CB1 receptors is dangerously high.

Consequently, unlike natural THC, they trigger severe sympathomimetic crises,

extreme tachycardia and hypertension, alongside acute kidney injury and violent hallucinations.

These are catastrophic clinical presentations that standard cannabis simply does not produce.

And worse,

these synthetic molecules are totally invisible to standard THC drug tests.

Which makes diagnosing the intoxication in the ER extremely difficult.

Okay, so we've explored massive sympathetic stimulation and profound sensory distortion.

For part four, we are completely pivoting the pharmacological direction.

We are looking at molecules that slam the brakes on the central nervous system.

Right, we are diving into ethanol.

Ethanol is a broad spectrum general CNS depressant that operates via a powerful dual mechanism.

So it basically shuts the brain down.

It fundamentally dampens neuronal firing.

Ethanol enhances the inhibitory tone of the brain by augmenting the effects of GABA, the primary inhibitory neurotransmitter.

And simultaneously,

it triggers the release of endogenous opioids, which provides the positive reinforcement and euphoria associated with early intoxication.

Now, the metabolic pathway of ethanol is a mandatory concept for any student of pharmacology to master.

Let's conceptually walk through a figure 45 .7.

It requires two distinct hepatic enzymes.

First, alcohol dehydrogenase, or ADH, oxidizes the ethanol molecule into acetaldehyde, which is a highly toxic reactive intermediate.

Extremely toxic.

So the liver must immediately deploy a second enzyme, aldehyde dehydrogenase, or ALDH, to convert that toxic acetaldehyde into acetate, which is a relatively harmless compound that the body easily excretes.

But the defining pharmacokinetic fact of this entire process is its absolute metabolic bottleneck.

Ethanol clearance is governed by zero order elimination kinetics.

And that is so important to grasp.

Think of it as a rigidly controlled toll booth on a major highway.

It does not matter if there are two cars waiting or a 10 -mile traffic jam.

The toll booth only processes one car per minute.

That's a great analogy.

So the human liver can only eliminate approximately 15 to 40 milligrams per deciliter of ethanol per hour.

Exactly.

It operates at maximum capacity instantly.

Any consumption that exceeds that fixed hourly rate simply backs up, accumulating in the bloodstream and escalating the central nervous system depression.

And the specific metabolic vulnerability is exactly what clinical pharmacology exploits to treat alcohol dependence.

So how can pharmacology actually help someone quit?

Let's talk about the three medications detailed in the chapter.

First, there's desulphuram, which is essentially chemical aversion therapy.

If you look at figure 45 .12, desulphuram operates by irreversibly inhibiting that second enzyme, ALDH.

So it jams the toll booth halfway through the process.

Precisely.

The ethanol is converted into acetaldehyde, but it cannot be processed into acetate.

The toxic intermediate rapidly accumulates in the blood.

So if a patient on desulphuram consumes even a fractional amount of ethanol, what happens?

They experience immediate, intense flushing,

extreme tachycardia, hyperventilation, and debilitating nausea.

It is a punishing and negative reinforcement mechanism designed to enforce absolute abstinence.

Wow.

And then there's a less punitive pharmacological strategy, right?

Using naltrexone.

Yes, because ethanol relies on the release of endogenous opioids to generate its rewarding effects.

Introducing a long -acting competitive opioid antagonist like naltrexone blocks those receptors.

It directly blunts the neurological reward.

Exactly, which significantly decreases the patient's craving for alcohol, and it's much better tolerated than desulphuram.

And the third therapeutic option is acamprosate.

Right.

Acamprosate targets the neurological imbalance created by chronic alcohol exposure.

It decreases cravings by modulating the NMDA -mediated glutamatergic pathways.

It's attempting to quiet the hyper -excitable state of a brain that is adapting to constant depression.

And understanding that state of adaptation is absolutely crucial for managing acute withdrawal.

Which brings us to another great study question tie -in.

Imagine a scenario where a chronic, heavy drinker is hospitalized after a car crash.

They're suddenly deprived of alcohol, and they begin seizing.

What is the physiological mechanism there?

Well, chronic exposure to ethanol forces the brain to constantly operate under a heavy blanket of GABA -mediated inhibition.

To survive, the central nervous system compensates.

It down -regulates its GABA receptors and drastically up -regulates its excitatory glutamatergic pathways.

So when that massive inhibitory blanket is suddenly ripped away.

The brain is left with unopposed, extreme excitatory signaling.

The clinical result is severe autonomic hyperactivity, profound agitation, tremors, hallucinations, and as you mentioned, life -threatening generalized seizures.

And the immediate pharmacological imperative is to prevent convulsive status epilepticus.

You have to artificially replace the lost inhibitory tone.

Which is why you manage it with a benzodiazepine like lorazepam.

Larazapam provides the necessary cross -tolerance.

It aggressively amplifies GABA signaling, suppressing the hyper -excitability, and safely managing the withdrawal cascade.

Incredible.

Moving from the acute management of withdrawal in the hospital brings us to part 5, our final stop on this deep dive.

And arguably, it's the most devastating pharmacological landscape.

The epidemic of abuse originating directly from legitimate medical prescriptions.

The historical data regarding opioid prescribing is just staggering.

To understand the current crisis, you have to examine the paradigm shift that occurred between 1997 and 2007.

The medical community initiated a massive push to designate and treat pain as the fifth vital sign.

And this resulted in an unprecedented 600 % surge in the prescribing of opioid analgesics.

600%.

That aggressive approach to pain management was paired with a really catastrophic minimization of the profound physical dependence these molecules induce.

By 2010, the sheer mass of opioid pain relievers distributed in the U .S.

was enough to supply every single American adult with a continuous round -the -clock dose of hydrocodone for an entire month.

And the resulting mortality data, visualized in figure 45 .33, paints a grim picture.

If you track the overdose fatalities associated with classic heroin or clinical methadone, the lines on the graph demonstrate a steady, insidious climb over the decades.

They sort of flatlined or arose slowly.

But the trajectory for synthetic opioids tells a completely different story.

Entirely different.

Right around 2014 and 2015, that line diverges violently, spiking almost vertically.

And that massive, sharp spike is entirely driven by the introduction of synthetic opioids like fentanyl and its ultra -potent derivatives like carfentanil into the illicit supply chain.

Yes.

These molecules are deployed as invisible adulterants, vastly amplifying the lethality of street heroin.

And the pharmacology of fentanyl makes reversing it exceptionally difficult.

Because its binding affinity and sheer potency just completely dwarf that of standard morphine.

Exactly.

When a patient presents with a fentanyl -induced respiratory arrest,

standard naloxone protocols frequently fail.

It requires massive, repeated doses of the antagonist to successfully compete for and displace the fentanyl from the mu -opioid receptors.

And that distinct pharmacological challenge directly fueled the catastrophic loss of life, contributing to the more than 33 ,000 deaths in 2015 alone.

It's a tragic reality of modern pharmacology.

It really is.

And we began this deep dive by defining rogue pharmacology as a microscopic arms race.

The opioid crisis is arguably its most lethal battleground.

Underground laboratories continuously synthesize novel fentanyl analogs specifically engineered to outmaneuver legislation in standard toxicology screens.

While clinical pharmacology is racing to develop stronger antagonists and more effective addiction therapies.

And I think that's a final, provocative thought to really leave the listener with to mull over.

Notice how throughout this entire chapter, from n -bomb replacing LSD to bath salts mimicking cocaine to synthetic fentanyl -contaminating heroin, the underground chemistry of receptor binding is constantly evolving purely to outpace legal detection.

You aren't just studying a list of side effects or memorizing static drugs.

You are studying an ongoing microscopic arms race.

You're studying the inherent structural vulnerabilities of the human nervous system and the chemical agents specifically designed to exploit them.

Grasping that foundational receptor logic,

understanding exactly why a molecule behaves the way it does, is your absolute greatest asset as a student.

Perfectly said.

On behalf of the Last Minute Lecture Team, thank you for letting us guide you through this complex landscape.

Keep that arms race perspective front and center as you continue your studies.

And best of luck conquering pharmacology.